NEW YORK--(BUSINESS WIRE)--Viriathus Research LLC, an independent research firm, issued an Update Report today on Shandong Luoxin Pharmacy Stock Co., Ltd., (OTCQX: SLUXY - SEHK: 8058), a company which develops, manufactures and markets pharmaceutical products in the People's Republic of China. The Company offers a wide variety of Western medicines as well as bulk medicines - more than 240 products in all. The Company was founded in 1995 and is based in China's Linyi City.
The update report provides a description of Shandong's business, industry, product, strategy, management team, and investment opportunities and risks.
If you would like a complimentary copy of this report please go to: http://www.viriathus.com/.
About Viriathus Research LLC
Viriathus Research is a quality-leading New York based independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutions that invest in them.
For further information on Viriathus Research, please visit www.viriathus.com.
About Shandong Luoxin Pharmacy Stock Co., Ltd.
Shandong Luoxin Pharmacy Stock Co., Ltd. develops, manufactures and markets pharmaceutical products in the People's Republic of China. The Company offers a wide variety of Western medicines as well as bulk medicines - more than 240 products in all. The Company was founded in 1995 and is based in China's Linyi City. Shandong Luoxin shares began trading on the Hong Kong Stock Exchange ("HKEx") in 2005, moved to the Main Board in 2008 and began trading on the OTCQX market as "SLUXY" in 2009.
For further information on Shandong Pharmacy Stock Co., Ltd., please visit http://www.luoxin.cn/en/index.asp.
Statement under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.
Viriathus Research has issued this report in connection with Viriathus Capital LLC Series' ("Viriathus Capital") OTCQX Advisory service for Shandong Luoxin Pharmacy Stock Co., Ltd., for which Viriathus Capital will be compensated US$100,000.00 annually.